On the economic front, U.S. initial jobless
claims rose last week for the first time since March, raising fears that the
emerging economic recovery could be in peril. These economic concerns were
compounded by uncertainty over the renewal of U.S. fiscal
stimulus, which has been integral to the stabilization and subsequent
economic rebound since the rapid plummet towards recession in March.
Critical relief measures from Congress's initial stimulus
package, including unemployment benefits, small business loans, mortgage and
rental forbearances are set to expire at the end of the July. With the
coronavirus pandemic showing no signs of abating, the failure to extend these
benefits could have a devastating impact on our economic rebound and general
consumer sentiment. Adding to the downward pressure on market sentiment was the
tit-for-tat closures of consulates in the U.S. and China. This follows a
pattern of sharpening U.S.-Sino tensions, which raises another obstacle to the
global economic recovery.
For the week, the DJIA, S&P, and Nasdaq
shed 0.8%, 0.3%, and 1.3% respectively. This snapped two and three week winning
streaks for the DJIA and S&P 500. Underscoring this week's risk-off rally,
the U.S. 10
Treasury dropped to 0.58% and gold rose to a new record price of $1,897.50 a
troy ounce.
ETFG Weekly Select List -
The five most highly rated ETFs per Sector, Geographic Region and Strategy as
ranked by the ETFG Quant model.
Given that the development of a
COVID-19 vaccine currently wields an outsize influence on market sentiment,
we'd like to highlight ETFs from the health care sector that our model
currently favors. The following five 5, ranked 1-5 according to our model,
could offer upside exposure towards COVID-19 therapeutics and vaccine progress
- SPDR S&P Biotech ETF (XBI), Loncar Cancer Immunotherapy ETF (CNCR),
iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH), and
VanEck Vectors Pharmaceutical ETF (PPH).
Thanks for reading ETF Global Perspectives!
ETFG 21 Day Free Trial: https://www.etfg.com/signup/quick
_______________________________________________________
Assumptions, opinions and
estimates constitute our judgment as of the date of this material and are
subject to change without notice. ETF
Global LLC (“ETFG”) and its affiliates and any third-party providers, as well
as their directors, officers, shareholders, employees or agents (collectively
ETFG Parties) do not guarantee the accuracy, completeness, adequacy or
timeliness of any information, including ratings and rankings and are not
responsible for errors and omissions or for the results obtained from the use
of such information and ETFG Parties shall have no liability for any errors,
omissions, or interruptions therein, regardless of the cause, or for the
results obtained from the use of such information. ETFG PARTIES DISCLAIM ANY
AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO ANY
WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OR USE.
In no event shall ETFG Parties be
liable to any party for any direct, indirect, incidental, exemplary,
compensatory, punitive, special or consequential damages, costs, expenses,
legal fees, or losses (including, without limitation, lost income or lost
profits and opportunity costs) in connection with any use of the information
contained in this document even if advised of the possibility of such damages.
ETFG ratings and rankings are
statements of opinion as of the date they are expressed and not statements of
fact or recommendations to purchase, hold, or sell any securities or to make
any investment decisions. ETFG ratings and rankings should not be relied on when
making any investment or other business decision. ETFG’s opinions and analyses do not address
the suitability of any security. ETFG
does not act as a fiduciary or an investment advisor. While ETFG has obtained information from
sources they believe to be reliable, ETFG does not perform an audit or
undertake any duty of due diligence or independent verification of any
information it receives.
This material is not intended as
an offer or solicitation for the purchase or sale of any security or other financial
instrument. Securities, financial instruments or strategies mentioned herein
may not be suitable for all investors.
Any opinions expressed herein are given in good faith, are subject to
change without notice, and are only correct as of the stated date of their
issue. Prices, values, or income from
any securities or investments mentioned in this report may fall against the
interests of the investor and the investor may get back less than the amount
invested. Where an investment is
described as being likely to yield income, please note that the amount of
income that the investor will receive from such an investment may
fluctuate. Where an investment or
security is denominated in a different currency to the investor's currency of
reference, changes in rates of exchange may have an adverse effect on the
value, price or income.